Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Washington Univ. School of Medicine S1PR1 compound 6h
- Development stage
- Unknown
- Lead developer
- Washington University School of Medicine
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Washington Univ. School of Medicine S1PR1 compound 6h: sourced facts only. name: "Compound 6h is potent (IC50 = 8.7 nM) and selective for S1PR1." [PMID:36926861]; target: "Compound 6h is potent (IC50 = 8.7 nM) and selective for S1PR1." [PMID:36926861]; developer: "Department of Radiology, Washington University School of Medicine, Saint Louis, Missouri 63110, United States." [PMID:36926861]; modality: "[18F]6h is a promising radioligand to image S1PR1 and worth translational clinical investigation for humans with brain disorders." [PMID:36926861]
Beyond the preview
Go deeper on Washington Univ. School of Medicine S1PR1 compound 6h.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Washington Univ. School of Medicine S1PR1 compound 6h.